Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease

Veronika Sharp, MD, Alice Chuang, MD, Lily Kao, MD, RMSK, & Midori Jane Nishio, MD, RhMSUS  |  November 9, 2017

A 57-year-old Ghanaian woman was referred to our rheumatology practice with acute, left elbow swelling and pain. The referring oncologist suspected gout, because the patient had hyperuricemia. Six months before, the patient was diagnosed with stage IV human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell lymphoma (ATLL). Her initial oncologic manifestations included multiple thoracic,…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportClinicalDiagnosisGouthyperuricemiamalignantoutcomepatient careRheumatic DiseaserheumatologyT cell lymphomaUltrasound

AndreyCherkasov / Shutterstock.com

Rheumatic Disease Does Not Preclude Pregnancy

Ruth Jessen Hickman, MD  |  November 9, 2017

Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

Filed under:Conditions Tagged with:Autoimmune diseasecontraceptivecounselingEducationInflammatory MyopathiesLupusoutcomepatient carepregnancyRheumatic DiseaseRheumatoid arthritisrheumatologistriskSystemic sclerosisVasculitisWomen

Physical Activity, Exercise Can Benefit Patients with RA

August Floden, PT, MS  |  November 9, 2017

While medical advances in rheumatoid arthritis (RA) have led to improvements in disease control and quality of life for patients worldwide, the rate for stable remission remains low.1 Management of RA symptoms is traditionally accomplished through a combination of medications and nonpharmacological interventions.2 This approach can prevent the development of secondary adverse health outcomes. Two…

Filed under:ConditionsPractice SupportRheumatoid Arthritis Tagged with:ExerciseMedicationpatient carephysical activityPhysical TherapyRARheumatoid arthritisrheumatologistrheumatology

Rheumatology Health Professionals’ Awards, Appointments and Announcements November 2017

Carol Patton  |  November 8, 2017

Dr. Sherine Gabriel Joins Board of Trustees In July, ACR Past President Sherine E. Gabriel, MD, MSc, joined the New York Academy of Medicine Board of Trustees. Dr. Gabriel is a distinguished professor and dean of Rutgers Robert Wood Johnson Medical School. As dean emerita of Mayo Medical School, Dr. Gabriel developed successful clinical research training and career development…

Filed under:Career DevelopmentProfessional TopicsResearch Rheum Tagged with:AwardsCareerProfilepromotionResearchrheumatologistrheumatology health professionals

Kentucky Accuses Endo of Contributing to Opioid Epidemic

Nate Raymond  |  November 7, 2017

(Reuters)—Kentucky accused units of Endo International Plc. on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. Kentucky Attorney General Steve Beshear said the lawsuit would seek to hold Endo responsible for illegally building a…

Filed under:AnalgesicsConditionsDrug UpdatesLegal UpdatesPain SyndromesProfessional Topics Tagged with:Chronic painlawsuitLegalOpioid abuseOpioidsPain

Systemic Sclerosis Mortality Rate May Be Underestimated

Kurt Ullman  |  November 6, 2017

Systemic sclerosis (SSc) is a disease characterized by immunologic abnormalities, microvascular involvement and tissue fibrosis. In previous studies, 10-year survival rates ranged from 50–84%. However, there are concerns that these studies, using prevalent cohorts, are underestimating mortality. “While the prognosis of many rheumatic diseases has improved with the availability of more effective and targeted therapies,…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:heart-lungmortalityorgan damagepatient careraterenal complicationResearchrheumatologistrheumatologyriskSclerodermastudysurvivalSystemic sclerosisTreatment

Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout

Simon M. Helfgott, MD  |  November 5, 2017

My dear electronic health records How do I dislike thee? Let me count the ways Adaptation of Sonnet 43 By Elizabeth Barrett Browning, 1806–1861 As my tenure as physician editor winds down, it’s worth reviewing some of the more nettlesome issues confronting clinicians that have been previously discussed in these pages and gauge their current…

Filed under:EMRsInsuranceOpinionPractice SupportRheuminationsSpeak Out RheumWorkforce Tagged with:burnoutCareercostsdrugEHRElectronic health recordsHealthcareinsurancepharmacy benefit managersphysicianPractice Managementrheumatologist

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

Filed under:Drug Updates Tagged with:Fentanylnational opioid addiction epidemicopioid crisisprescription painkillersU.S. public health emergency

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2017

The FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) to include manufacturers of immediate-release opioids. The makers of these drugs will soon be required to provide training and education to healthcare professionals on the proper prescription and use of the drugs for pain management…

Filed under:AnalgesicsDrug Updates Tagged with:FDAopioidOpioid abuseREMSU.S. Food and Drug Administration (FDA)

GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

Ben Hirschler  |  October 23, 2017

LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…

Filed under:Conditions Tagged with:FDA approvalshinglesShingrixU.S. Food and Drug Administration (FDA)vaccine

  • « Previous Page
  • 1
  • …
  • 107
  • 108
  • 109
  • 110
  • 111
  • …
  • 162
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences